BioGaia AB
St. Louis, Missouri
Profile updated: April 2, 2026
BioGaia AB is a Swedish probiotic company headquartered in Stockholm, Sweden. BioGaia specializes in Lactobacillus reuteri probiotic strains backed by over 270 clinical studies involving more than 23,000 subjects. Key strains include Protectis (DSM 17938, gut health), Prodentis (oral health), and Gastrus (gastric health). BioGaia operates a wholly owned US subsidiary, BioGaia USA, in St. Louis, Missouri (full ownership effective April 2026 after acquiring the remaining 20% of distributor Nutraceutics). BioGaia operates both as a consumer product company and as a B2B ingredient supplier licensing strains to other supplement manufacturers.
Directory Listing — Records Reviewed
Public records and independent sources have been reviewed.
What this means →Min. OrderMOQ (Minimum Order Quantity)The smallest production run a manufacturer will accept for an order.
Not publicly disclosed
Lead TimeLead TimeThe time from order placement to finished product delivery.
Not publicly disclosed
Product Types
L. reuteri Protectis (DSM 17938, Gut Health), L. reuteri Prodentis (Oral Health), L. reuteri Gastrus (Gastric Health), Probiotic Strain Licensing (B2B)
Capabilities
Probiotic Strain Development (L. reuteri Specialist), Clinical Research Program (270+ Studies), B2B Strain Licensing, Consumer Product Manufacturing, US Subsidiary Operations (St. Louis, MO)
Certifications
0 of 1 certification independently confirmed. What this means
Key Regulatory Concepts
Dietary supplement manufacturers must comply with 21 CFR Part 111 (Current Good Manufacturing Practice for dietary supplements). This includes requirements for personnel, facilities, equipment, production, laboratory operations, and record-keeping.
Review Notes
Swedish probiotic specialist, Stockholm HQ. L. reuteri strains backed by 270+ clinical studies, 23,000+ subjects. BioGaia USA in St. Louis, MO became wholly owned subsidiary April 2026 (acquired remaining 20% of Nutraceutics for $6.4M). Dual model: consumer products + B2B strain licensing. US is largest market since 2021, Americas growth 42% in 2025. NutraIngredients and TipRanks coverage confirm industry standing and US operations.
Sources
- BioGaia Group — Clinical Studies(2026-04-02)
- BioGaia Acquires Full Ownership of US Distributor Nutraceutics(2026-04-02)
Disclosures
- No material connection exists between Inventory Ready and this company
Interested in BioGaia AB?
Tell us about your project and we'll help you determine if this ingredient supplier is a good fit.